Heart failure & cardiomyopathiesRandomised controlled trial
Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)
- Randomised controlled trial
- double-blind
- placebo-controlled
- multicentre
Authors' conclusion
In patients with left ventricular systolic dysfunction after an acute MI receiving contemporary standard of care, treatment with empagliflozin had no effect on cardiac volumes or LVEF compared with placebo.
Study context
- Population
- Patients ≥12 h and ≤14 days after acute myocardial infarction (MI) with left ventricular ejection fraction (LVEF) <45% by magnetic resonance imaging (MRI)
- Participants
- 105 patients
- Comparison
- Empagliflozin vs placebo
- Primary endpoint
- Change in LV end-systolic volume indexed to body surface area (LVESVI)
- Follow-up
- Baseline to 24 weeks
Primary result
Change in LVESVI · 24 weeks
Between-group difference
0.3 ml/m²
95% CI −5.2 to 5.8
P = 0.92
By group
Placebo
7.8
mean decrease · SD 16.3 · ml/m²
Empagliflozin vs Placebo
between-group difference 0.3 ml/m² (95% CI −5.2 to 5.8); P = 0.92
As reported in the abstract
Secondary outcomes
Left ventricular end-diastolic volume index (LVEDVI), LVEF, left atrial volume index, LV mass index, NT-proBNP, high-sensitivity troponin I (hs-TnI)
- No effect of empagliflozin vs placebo
Haematocrit, uric acid, weight
- Empagliflozin increased haematocrit and reduced uric acid and weight
Original publication
Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI). Eur J Heart Fail. Published 15 December 2024. doi:10.1002/ejhf.3560
Summarised from the published abstract; every number is checked against it